SETDB1 and hepatocellular carcinoma: In summary, SETDB1 could activate AKT T308 and S308 phosphorylation sites by promoting methylation of AKT on K64me3 site, thereby accelerating the tumorigenesis and chemotherapy resistance of HCC cells in nude mice.